Drugs / GSK2231395A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00849069 | Mar → Apr 2009 | haemophilus infectious disease, pneumococcal infection | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT00814489 | Jan → May 2009 | haemophilus infectious disease, pneumococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2231395A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00849069 ↗ |
| Modality | Vaccine | “GSK2231395A candidate vaccine” NCT00849069 ↗ |